Prescient Therapeutics logo

PTX - Prescient Therapeutics Share Price

A$0.087 0.0  0.0%

Last Trade - 10/05/21

Micro Cap
Market Cap £31.3m
Enterprise Value £20.9m
Revenue £37.5k
Position in Universe 1093rd / 1907
Unlock PTX Revenue
Relative Strength (%)
1m -19.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -40.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.040 0.011 0.17 0.13 0.072 0.070 +12.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, PrescientTherapeutics Ltd revenues decreased 9% to A$38K. Net lossincreased 6% to A$1.8M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsShare based payments increase from A$107K to A$263K(expense), Research and development costs increase of 4% toA$1.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


PTX Revenue Unlock PTX Revenue

Net Income

PTX Net Income Unlock PTX Revenue

Normalised EPS

PTX Normalised EPS Unlock PTX Revenue

PE Ratio Range

PTX PE Ratio Range Unlock PTX Revenue

Dividend Yield Range

PTX Dividend Yield Range Unlock PTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PTX EPS Forecasts Unlock PTX Revenue
Profile Summary

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The Company is engaged in developing compounds to treat a range of solid and hematological cancers. It is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated May 22, 1986
Public Since June 12, 2013
No. of Shareholders: 5,326
No. of Employees: 3
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 640,553,010
Free Float (0.0%)
Eligible for
PTX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for PTX
Upcoming Events for PTX
Frequently Asked Questions for Prescient Therapeutics
What is the Prescient Therapeutics share price?

As of 10/05/21, shares in Prescient Therapeutics are trading at A$0.087, giving the company a market capitalisation of £31.3m. This share price information is delayed by 15 minutes.

How has the Prescient Therapeutics share price performed this year?

Shares in Prescient Therapeutics are currently trading at A$0.087 and the price has moved by 85.11% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Prescient Therapeutics price has moved by 38.69% over the past year.

What are the analyst and broker recommendations for Prescient Therapeutics?

Of the analysts with advisory recommendations for Prescient Therapeutics, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Prescient Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Prescient Therapeutics next release its financial results?

Prescient Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Prescient Therapeutics dividend yield?

Prescient Therapeutics does not currently pay a dividend.

Does Prescient Therapeutics pay a dividend?

Prescient Therapeutics does not currently pay a dividend.

When does Prescient Therapeutics next pay dividends?

Prescient Therapeutics does not currently pay a dividend.

How do I buy Prescient Therapeutics shares?

To buy shares in Prescient Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Prescient Therapeutics?

Shares in Prescient Therapeutics are currently trading at A$0.087, giving the company a market capitalisation of £31.3m.

Where are Prescient Therapeutics shares listed? Where are Prescient Therapeutics shares listed?

Here are the trading details for Prescient Therapeutics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: PTX
What kind of share is Prescient Therapeutics?

Based on an overall assessment of its quality, value and momentum, Prescient Therapeutics is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Prescient Therapeutics share price forecast 2021?

Shares in Prescient Therapeutics are currently priced at A$0.087. At that level they are trading at 0.13% discount to the analyst consensus target price of 0.00.

Analysts covering Prescient Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.012 for the next financial year.

How can I tell whether the Prescient Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prescient Therapeutics. Over the past six months, the relative strength of its shares against the market has been 19.98%. At the current price of A$0.087, shares in Prescient Therapeutics are trading at 9.74% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Prescient Therapeutics PE Ratio?

We were not able to find PE ratio data for Prescient Therapeutics.

Who are the key directors of Prescient Therapeutics?

Prescient Therapeutics's management team is headed by:

Steven Engle - NEC
James Campbell - NED
Steven Yatomi-Clarke - CEO
Melanie Leydin - SEC
Terrence Chew - OTH
Said Sebti - CSO
Allen Ebens - NED
Who are the major shareholders of Prescient Therapeutics?

Here are the top five shareholders of Prescient Therapeutics based on the size of their shareholding:

Australian Ethical Investment Ltd. Investment Advisor
Percentage owned: 4.72% (30.2m shares)
Retzos Executive Pty. Ltd. Corporation
Percentage owned: 2.96% (19.0m shares)
Stewart (Andrew Morrison) Individual Investor
Percentage owned: 1% (6.43m shares)
Daly (Richard Thomas Hayward) Individual Investor
Percentage owned: 0.9% (5.76m shares)
Yatomi-Clarke (Steven) Individual Investor
Percentage owned: 0.8% (5.14m shares)
Similar to PTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.